Fintel reports that on May 29, 2024, HC Wainwright & Co. initiated coverage of Cognition Therapeutics (NasdaqGM:CGTX) with a Buy recommendation.
Analyst Price Forecast Suggests 234.98% Upside
As of May 22, 2024, the average one-year price target for Cognition Therapeutics is 6.80. The forecasts range from a low of 5.05 to a high of $9.45. The average price target represents an increase of 234.98% from its latest reported closing price of 2.03.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cognition Therapeutics is 0MM. The projected annual non-GAAP EPS is -1.85.
What is the Fund Sentiment?
There are 63 funds or institutions reporting positions in Cognition Therapeutics. This is an increase of 10 owner(s) or 18.87% in the last quarter. Average portfolio weight of all funds dedicated to CGTX is 0.04%, an increase of 32.74%. Total shares owned by institutions decreased in the last three months by 1.86% to 9,380K shares.
What are Other Shareholders Doing?
Pathstone Family Office holds 2,205K shares representing 5.51% ownership of the company. In its prior filing, the firm reported owning 2,210K shares , representing a decrease of 0.23%. The firm decreased its portfolio allocation in CGTX by 19.13% over the last quarter.
AIGH Capital Management holds 1,897K shares representing 4.74% ownership of the company. In its prior filing, the firm reported owning 2,039K shares , representing a decrease of 7.46%. The firm decreased its portfolio allocation in CGTX by 44.60% over the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 689K shares representing 1.72% ownership of the company. In its prior filing, the firm reported owning 510K shares , representing an increase of 25.94%. The firm increased its portfolio allocation in CGTX by 21.11% over the last quarter.
AWM Investment holds 650K shares representing 1.62% ownership of the company.
Alyeska Investment Group holds 500K shares representing 1.25% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
